Related Experiment Video
Updated: Dec 7, 2025
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
MiRNA, a New Treatment Strategy for Pulmonary Fibrosis
Yanhong Liu1, Hongguang Nie1, Yan Ding1
1Department of Stem Cells and Regenerative Medicine, College of Basic Medical Science, China Medical University, Shenyang, China.
Abstract:
Pulmonary fibrosis (PF) is the most common chronic, progressive interstitial lung disease, mainly occurring in the elderly, with a median survival of 2-4 years after diagnosis. Its high mortality rate attributes to the delay in diagnosis due to its generic symptoms, and more importantly, to the lack of effective treatments. MicroRNAs (miRNAs) are a class of small non-coding RNAs that are involved in many essential cellular processes, including extracellular matrix remodeling, alveolar epithelial cell apoptosis, epithelial-mesenchymal transition, etc. We summarized the dysregulated miRNAs in TGF-β signaling pathway-mediated PF in recent years with dual effects, such as anti-fibrotic let-7 family and pro-fibrotic miR-21 members. Therefore, this review will set out the latest application of miRNAs to provide a new direction for PF treatment.
Insights
MicroRNAs show dual roles in pulmonary fibrosis (PF) pathogenesis. Targeting these microRNAs offers a promising new therapeutic strategy for treating this progressive lung disease.
Area of Science:
- Biochemistry
- Molecular Biology
- Pulmonology
Background:
- Pulmonary fibrosis (PF) is a progressive, fatal interstitial lung disease with limited treatment options.
- Delayed diagnosis and lack of effective therapies contribute to PF's poor prognosis.
- MicroRNAs (miRNAs) are key regulators of cellular processes implicated in fibrosis.
Purpose of the Study:
- To review the dual roles of dysregulated microRNAs in TGF-β signaling-mediated pulmonary fibrosis.
- To explore the potential of miRNAs as therapeutic targets for PF treatment.
Main Methods:
- Literature review of recent studies on microRNAs and pulmonary fibrosis.
- Analysis of the involvement of specific miRNAs (e.g., let-7 family, miR-21) in fibrotic pathways.
Main Results:
- Certain miRNAs, like the let-7 family, exhibit anti-fibrotic effects.
- Other miRNAs, such as miR-21, promote fibrotic processes in PF.
- Dysregulated miRNAs are implicated in extracellular matrix remodeling and cell apoptosis in PF.
Conclusions:
- MicroRNAs play complex, often opposing roles in the pathogenesis of pulmonary fibrosis.
- Targeting specific microRNAs presents a novel therapeutic avenue for pulmonary fibrosis.
- Further research into miRNA-based therapies could improve outcomes for PF patients.
